Search PubMed⌕ Search

Biomedical subjects

H Inaji

Publications and source records attributed to H Inaji.

At least 91 records · Page 5Linked to original sources
PubMed1988

[Stromal sarcoma of the breast following augmentation mammoplasty--a case report].

A case of a stromal sarcoma of the breast that developed after augmentation mammoplasty is presented. A 55-year-old woman, who had received mammoplasty twenty years earlier, was referred to our hospital due to a mass in her left breast. A diagnosis of myxoid sarcoma was determined by an incisional biopsy and a radical mastectomy was performed. A pathological specimen, however, revealed the mass to be a stromal sarcoma because of its metaplastic heterogeneous elements, such as bone, cartilage, and muscle. We also present previous cases, and discuss the matter of diagnosis and therapy.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1987

Carcinoembryonic antigen estimation in nipple discharge as an adjunctive tool in the diagnosis of early breast cancer.

To assess the usefulness of carcinoembryonic antigen (CEA) estimation in nipple discharge for the detection of nonpalpable breast cancer, CEA activity in nipple discharge was measured by enzyme immunoassay using monoclonal antibody. The specificity of the antibody for breast cancer was assessed by an immunohistochemical method. Mean CEA levels in the nipple discharge from 18 patients with benign breast diseases (ten intraductal papilloma; eight fibrocystic disease) was 43 ng/ml (SD, 34 ng/ml), suggesting an upper reference limit of 100 ng/ml. Six of seven nonpalpable breast cancer patients had higher CEA levels than this tentative cutoff value, as did three of five patients with borderline lesions. The incidence of elevated CEA levels in nipple discharge correlated significantly with the incidence of intratumoral antigen expression. These results lead us to conclude that CEA measurement in nipple discharge may be a useful adjunct in the diagnosis of nonpalpable breast cancer.

Adult↗
PubMed1987

Purification and characterization of a pancreas cancer-related antigen.

A pancreatic cancer-related antigen (PCRA) has been identified, isolated and characterized from liver metastases of pancreatic carcinoma. The purified PCRA was homogeneous by polyacrylamide disc gel electrophoresis, had an Mr of about 500,000, consisted of 30% carbohydrate and 70% protein, and migrated in the alpha 2-beta region in electrophoresis. In gel immunoprecipitation the antiserum against PCRA reacted with extracts of pancreatic cancer and spleen, but neither with normal human serum nor with normal pancreas, liver, lung, large and small intestine extracts. It clearly differed from other known pancreatic tumor-associated antigens.

Antigens, Neoplasm↗
PubMed1987

Usefulness of carcinoembryonic antigen measurement in feces of patients with colorectal cancer.

Anticarcinoembryonic antigen (CEA) antisera which showed no reactions with normal adult feces were prepared in guinea pigs. Using these, levels of CEA in feces from patients with colorectal carcinoma were measured by gel diffusion and rocket immunoelectrophoresis. Sixteen of 22 (73 percent) patients with carcinoma of the colon or rectum (Dukes' A4/6, B6/8, C6/7, D0/1) had detectable CEA in their feces, while none was detected in the feces of four patients with gastric ulcers or in those of 22 normal volunteers. Five of the 16 fecal CEA-positive patients showed no elevation of plasma CEA levels. Measurements using a commercial CEA kit (Abbott Laboratories) could not detect the differences between fecal CEA values of patients with colorectal carcinoma and benign diseases, or those of normal volunteers. These results suggest that measurement of fecal CEA by specific anti-CEA antisera will be valuable in screening and diagnosis of colorectal carcinoma.

Carcinoembryonic Antigen↗
PubMed1987

[A case of a non-invasive carcinoma of the breast with unusual clinicopathological appearance].

A rare case of a non-invasive carcinoma of the breast is reported. A 39-year-old woman was admitted to our hospital complaining of large breast lump (11.5 X 8.0 cm) and an abnormal nipple discharge. Mammography revealed widely dispersed microcalcifications and an echographic diagnosis indicated a fibrocystic disease. A cytologic examination of the nipple discharge showed malignant cells with a CEA level that was very high. The patient was treated with a standard radical mastectomy. Specimen mammography showed microcalcification in almost all sections. The histological examination, using serial sections, was seen to be consistent with a non-invasive ductal carcinoma. No lymph node or remote distant metastasis was found.

Adult↗
PubMed1984

[A case of recurrent breast cancer responding to long-term administration of tamoxifen].

A 44-year-old premenopausal woman with metastatic breast cancer to the bones was treated with tamoxifen and tegafur followed by a minimal dose of tamoxifen alone, with complete response for more than 90 months. Initially, tamoxifen was given with a dose of 20 mg daily in combination with 600 mg daily of tegafur for 22 months, a remission of low back pain and recalcification of the lytic lesion in the pelvis. After reduction of tamoxifen dose to 10 mg/daily and withdrawal of tegafur, regression of the disease continued for another 68+ months. Bone metastasis completely disappeared, and the patient is still in remission. No significant side effects from tamoxifen were encountered. Tamoxifen appears to be a useful and safe treatment for recurrent breast cancer.

Adult↗
PubMed1984

[Intra-arterial infusion of adriamycin in the treatment of locally advanced breast cancer].

Intra-arterial infusion chemotherapy was performed in 27 patients with locally advanced breast cancer. Through two catheters placed in the subclavian artery and the internal mammary artery, 30-50 mg of ADM was injected intermittently with/without continuous infusion of 5-FU. Higher response rate was noted in cases treated with ADM alone (80.0%, 16/20) in comparison with ADM-5-FU (57.1%, 4/7). Overall response rate was 74.1% (20/27). The correlation between the total dose of ADM infused and the rate of tumor regression was observed. Out of 18 cases who received 120 mg or more of ADM, 16 cases (88.9%) showed tumor regression greater than 50%, in contrast to 4 of 9 (44.4%) cases who received less than 120 mg of ADM. A significantly higher concentration of ADM was detected in tumor tissues obtained one hour after intra-arterial injection of ADM, compared with patients who received intravenous injection of ADM. The side effects due to this course of treatment were considered to be tolerated. Prognostically, although no definite correlation was observed between clinical or pathological effects and survival rate, a more favorable prognosis seems to be expected with this treatment compared with other forms of therapy.

Breast Neoplasms↗
PubMed1984

Simultaneous evaluation of a pancreas-specific antigen and a pancreatic cancer-associated antigen in pancreatic carcinoma.

A pancreas cancer-associated antigen (PCAA) and a pancreas-specific antigen (PaA) were simultaneously quantitated by enzyme-linked immunosorbent assays in serum specimens from 51 normal controls, 76 pancreatic cancers, 194 nonpancreatic cancers, and 22 benign pancreatic diseases. Primary immunological reagents used in the enzyme-linked immunosorbent assays were our polyclonal antibodies produced in rabbits against purified PCAA and PaA. Results revealed discordance of these two markers in pancreatic cancer, suggesting that the presence of these two biochemically and immunologically distinct pancreas proteins in patients' serum may reflect different biological aspects of cancer. The combination test resulted in a better sensitivity and specificity for pancreatic cancer, 90 and 85%, respectively, than either PCAA or PaA assay alone. This study demonstrated that the combination of serum PCAA and PaA tests yields an additive clinical value and may be a useful adjunctive aid for the immunodiagnosis of the pancreatic cancer.

Antigens, Neoplasm↗
PubMed1983

Differential distribution of the pancreatic cancer-associated antigen (PCAA) and pancreatic tissue antigen (PaA) in pancreatic and gastrointestinal cancer tissues.

PCAA, a glycoprotein antigen fractionated from the ascites fluid of a patient with pancreatic cancer and sharing an identical immunogenicity with Gelder's POA, and PaA, a novel pancreatic tissue antigen, were studied immunohistologically. Serial paraffin sections were prepared from surgical specimens of 11 cases of pancreatic cancer, 15 of gastric cancer, 12 of colonic cancer, and 2 of gallbladder cancer; these were then subjected to immunofluorescence and immunoperoxidase stainings. In noncancerous tissues, PCAA was detected unexpectedly at goblet cells of the whole intestine, but was completely absent in pancreatic tissues, while PaA was not demonstrated in intestinal tissues, but was positive at acinar cells of the pancreas. In pancreatic cancer tissues, PCAA and PaA were detected at apical cytoplasm of cancer cells, although positive cells were in different proportions and had different distributions. PCAA-positive cells were mucin-producing (positive in PAS-alcian blue staining) and were well differentiated histologically, while PaA-positive cells were less differentiated and poor in mucin production. Among 11 cases of pancreatic cancer, both PCAA- and PaA-positive cells were demonstrated in 3 cases, PCAA-positive cells alone were found in 3 cases, and PaA-positive cells alone were seen in 4 cases. In 27 gastrointestinal cancer tissues, PCAA was detected in 7 cases of mucin-producing cancer, and PaA was demonstrated in 2 cases of poorly differentiated adenocarcinoma.

Adenocarcinoma↗
PubMed1982

Multiple marker evaluation in human prostate cancer with the use of tissue-specific antigens.

Serum prostate-specific antigen and prostatic acid phosphatase were simultaneously evaluated in 22 healthy males, 29 patients with benign prostatic hypertrophy, and 192 patients with prostate cancers at various stages as well as in 30 patients with cancers other than prostate cancer. Both markers were quantitated by specific sandwich-type, enzyme-linked, immunosorbent assays with the use of specific antiserum reagents. Serum assays revealed a discordance between these two markers; thus expressions of these two biochemically and immunologically distinct prostate-specific proteins may reflect different aspects in the biology of prostate cancer. A combination test with the use of 7.5 ng of prostate antigen and 15.5 ng of prostatic acid phosphatase/ml of serum, respectively, as cutoff values resulted in a positive detection rate of 58% for prostate cancers of stages A (7/12) and B (21/36) each, 68% for prostate cancer of stage C (19/28), 92% for prostate cancer of stage D (106/116), and only 10% for benign prostatic hypertrophy (3/29). None of 52 other cancers or healthy controls was registered as positive. This study demonstrates that a multiple marker test of tissue-specific antigens can be of an additive value in the immunodiagnosis of cancer and may be a logical and effective approach at this time, in light of the unavailability of human tumor-specific markers.

Acid Phosphatase↗
PubMed1981

Evaluation of a human pancreas-specific antigen by enzyme-linked immunosorbent assay.

A sensitive sandwich-type enzyme immunosorbent assay has been developed for quantitation of a new human pancreas-specific antigen (PaA). With this method, PaA at a concentration as low as 0.8 ng/ml can be detected. The assay was reproducible as shown by the coefficients of variation for within (4.8%) and between (6.1%) assays. Serum PaA levels from 51 healthy persons ranged from less than 4 to 34 ng/ml. Using 21.5 ng/ml (the upper 97.5 percentile of normal controls) as an upper limit, 42 of 60 pancreatic cancer (70%), 3 of 14 pancreatitis (21%) and 2 of 6 cholelithiasis (33%) had an elevated PaA. Very few patients with other cancers were shown to have an elevated PaA: 3/40 (8%) of lung cancer, 2/43 (5%) of colorectal cancer, 3/40 (8%) of prostate cancer and 1/39 (3%) of breast cancer. The sensitivity and specificity of the serum PaA test for the detection of pancreatic cancer were calculated to be 70% and 95%, respectively. These results indicate that PaA may be useful as an adjunctive tool in immunodiagnosis of pancreatic cancer.

Antigens, Neoplasm↗
PubMed1981

Use of human prostate-specific antigen in monitoring prostate cancer.

The newly reported human prostate-specific antigen (PA) is a specific histiotypic product of human prostate. With the use of a sensitive enzyme immunoassay, the circulating PA in prostatic cancer patients has been evaluated clinically. In 96 patients with advanced stage of disease (D2) and receiving chemotherapies, the pretreatment serum PA levels were found to be of prognostic value with regard to the patient survival. Ten patients with metastatic prostate cancer were monitored for more than 32 weeks by 183 serial PA values and were found generally to respond to the treatment. Additionally, in another group of 32 patients who underwent curative therapies for localized prostate cancer, 161 serum samples were evaluated during periods of 12 to 114 weeks (average 56 weeks). Of these patients, five developed metastases during follow-up, and all were shown to exhibit increasingly elevated PA values, either corresponding to or preceding the clinical diagnosis of disease recurrence. These results suggest that PA is a new marker with potential value to merit further clinical study.

Antigens, Neoplasm↗
PubMedDate not supplied

The possible prognostic significance of p53 immunostaining status of the primary tumor in patients developing local recurrence after breast-conserving surgery.

Prognostic factors for distant metastases in patients with local recurrence after breast-conserving treatment (BCT) were studied. Fifty-six patients who developed local recurrence after BCT were recruited from 18 key hospitals/institutes in Japan. All 10 patients whose primary tumors were DCIS fared well without evidence of distant failure for a median follow-up period of 57 months (range 41-72) after the local recurrence. Inflammatory local recurrence was observed in 5 patients whose prognosis was grave: 3 with concomitant distant metastases and 1 developing them 7 months later. In the remaining 41 patients with noninflammatory local recurrence, various clinicopathological factors including age, disease-free interval, histology of the primary and recurrent tumors, axillary lymph node status, estrogen and progesterone receptor, immunohistochemical staining of erbB2 and p53 protein were evaluated as prognostic factors. Only the p53 immunostaining status of the primary tumor was found to be a significant prognostic indicator for distant metastases; distant disease-free survival at 5 years after the local recurrence was 92% for patients with p53-negative cancers and 51% for those with p53-positive cancers (p < 0.05).

Adult↗